Peter McNamara, Chief Scientific Officer of Tectonic Therapeutic, Inc. (NASDAQ:TECX), filed a Form 4 on August 26, 2026, reporting a same-day option exercise and share sale on August 25, 2026, carried out under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: McNamara exercised an employee stock option covering 43 shares of common stock at an exercise price of $14.71 per share on August 25, 2026.
  • Shares sold: 43 shares of common stock were disposed of at $36.52 per share on the same date.
  • Remaining ownership: Following the transactions, McNamara directly beneficially owned 55,285 shares of common stock.
  • Options remaining: 7,787 employee stock options (right to buy) remain beneficially owned directly after the transaction.
  • Trading plan: The exercise and sale were made pursuant to a Rule 10b5-1 trading plan adopted by McNamara on November 14, 2025.
  • Vesting schedule: The underlying option vests in 48 equal monthly installments beginning October 25, 2025, subject to continued service, with an expiration date of September 24, 2035.

McNamara's Option Exercise and Sale Under 10b5-1 Plan

According to the filing, Peter McNamara, serving as Chief Scientific Officer of Tectonic Therapeutic, Inc., reported two transactions in Table I on August 25, 2026. First, he acquired 43 shares of common stock via an option exercise (transaction code M) at a price of $14.71 per share, bringing his direct holdings to 55,328 shares. He then disposed of those same 43 shares (transaction code S) at $36.52 per share, reducing his direct beneficial ownership to 55,285 shares.

The filing states that both the exercise and the subsequent sale were made pursuant to a Rule 10b5-1 trading plan that McNamara adopted on November 14, 2025. In Table II, the filing reports that the employee stock option carried an exercise price of $14.71, with an expiration date of September 24, 2035. The filing notes that the option shares vest in 48 equal monthly installments beginning on October 25, 2025, "subject to the Reporting Person's continued service to the Issuer on each such vesting date." Following the reported exercise, 7,787 derivative securities remain directly beneficially owned by McNamara.

The Form 4 was signed by Daniel Lochner as Attorney-in-Fact and filed on August 26, 2026. The filing indicates the transaction is not an amendment and was filed by one reporting person.

What Was Disclosed

The filing discloses a same-day option exercise and sale of 43 shares of Tectonic Therapeutic common stock by Chief Scientific Officer Peter McNamara on August 25, 2026, executed under a Rule 10b5-1 plan adopted November 14, 2025, leaving him with 55,285 shares and 7,787 options directly owned.